Evidence map›Paper›PMID 36084543›Full record

ArticlePsychiatry research2022

Psychiatric symptoms in COVID-19-positive individuals in the general population: Trajectories of depression, anxiety, and insomnia.

Sverre Urnes Johnson, Ole Myklebust Amundsen, Miriam Sinkerud Johnson, Asle Hoffart, Øyvind Halsøy, Nora Skjerdingstad, Sara Ebling, Omid V Ebrahimi

Abstract read
In one paragraph

Article in Psychiatry research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. A digital intervention for cognitive deficits following COVID-19: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  2. Article
  3. Article
  4. Article
  5. The Clinical Observation of Inflammation Theory for Depression: The Initiative of the Formosa Long COVID Multicenter Study (FOCuS).Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sverre Urnes JohnsonDepartment of Psychology, University of Oslo, Forskningsveien 3A, Harald Schjelderups hus, Oslo 0373, Norway; Modum Bad Psychiatric Hospital, Vikersund, Norway. Electronic address: s.u.johnson@psykologi.uio.no.
Ole Myklebust AmundsenDepartment of Psychology, University of Bergen, Norway.
Miriam Sinkerud JohnsonOslo Metropolitan University, Norway.
Asle HoffartDepartment of Psychology, University of Oslo, Forskningsveien 3A, Harald Schjelderups hus, Oslo 0373, Norway; Modum Bad Psychiatric Hospital, Vikersund, Norway.
Øyvind HalsøyDepartment of Psychology, University of Oslo, Forskningsveien 3A, Harald Schjelderups hus, Oslo 0373, Norway.
Nora SkjerdingstadDepartment of Psychology, University of Oslo, Forskningsveien 3A, Harald Schjelderups hus, Oslo 0373, Norway.
Sara EblingDepartment of Psychology, University of Bergen, Norway.
Omid V EbrahimiDepartment of Psychology, University of Oslo, Forskningsveien 3A, Harald Schjelderups hus, Oslo 0373, Norway; Modum Bad Psychiatric Hospital, Vikersund, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study investigates differences in the trajectories of anxiety, depression, and sleep problems among infected versus non-infected case-controlled individuals. Patients who tested positive for COVID-19 were selected from a representative sample in Norway (N > 10,000). In total, 126 of these individuals were infected during the project period, and this group was analyzed at T5 (May 2021). Of these positive cases, those who had completed both PHQ-9 and GAD-7 at all three measurement points were selected for longitudinal analysis using multilevel modeling. There was a significant difference at T5 between those who had tested positive for COVID-19 and matched controls. Anxiety and depression were reduced among those who tested positive, but there were no differences in trajectory when compared to matched controls. Limitations include the use of self-report measures and the assessment of symptoms at a time when strict virus mitigation protocols were in place. The present findings indicate that individuals who test positive for COVID-19 exhibit higher levels of depressive symptoms after restrictions are lifted. However, comparison of anxiety and depression symptom trajectories with matched controls reveals that both groups exhibited stable or slightly decreased symptoms.

Indexed as

COVID-19Sleep Initiation and Maintenance DisordersAnxietyAnxiety DisordersDepressionHumansAnxietyCOVID-19DepressionDescriptive survey studyLong COVID

Identifiers

PMID36084543
PMCPMC9392896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.